Atosiban acetate
Based on 7 publication(s) in Google Scholar
Atosiban acetate (RW22164 acetate;RWJ22164 acetate) is a nonapeptide competitive vasopressin/oxytocin receptor antagonist, and is a desamino-oxytocin analogue. Atosiban is the main tocolytic agent and has the potential for spontaneous preterm labor research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.87%
- CAS No.: 914453-95-5
- 화학식: C45H71N11O14S2
- 분자량:1054.24
-
보관:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Atosiban acetate
More- Neuron. 2026 Mar 26:S0896-6273(26)00120-0. [Abstract]
- Curr Biol. 2025 Sep 26:S0960-9822(25)01182-0. [Abstract]
- Transl Psychiatry. 2024 May 25;14(1):208. [Abstract]
- Neurosci Bull. 2025 Aug 6. [Abstract]
- Front Neurosci. 2021 Sep 10:15:723064. [Abstract]
- J Pharm Biomed Anal. 2023 Feb 5:224:115156. [Abstract]
- J Pharm Biomed Anal. 2022 Mar 20:211:114518. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IF
-
In Vivo Efficacy Study
All Vasopressin Receptor Isoforms
More
Biological Activity
Atosiban inhibits the oxytocin-mediated release of IP3 from the myometrial cell membrane. There is reduced release of intracellular, stored calcium from the sacroplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Atosiban blocks the activation of oxytocin-receptor-expressing neurons in the parabrachial nucleus of mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 914453-95-5
-
Appearance Solid
-
분자량 1054.24
-
화학식 C45H71N11O14S2
-
Color White to off-white
-
Synonyms
RW22164 acetate; RWJ22164 acetate
-
Sequence
{Mpa}-{d-Tyr(OEt)}-Ile-Thr-Asn-Cys-Pro-{Orn}-Gly-NH2 (disulfide bridge: Mpa1-Cys6)
-
Sequence Shortening
{Mpa}-{d-Tyr(OEt)}-ITNCP-{Orn}-G-NH2 (disulfide bridge: Mpa1-Cys6)
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Neuron
Dual anterior insula-prefrontal cortex circuits mediate chronic stress-induced social interaction deficits. [Abstract]2026 Mar 26:S0896-6273(26)00120-0. PMID: 41895265
Atosiban acetate purchased from MedChemExpress. Usage Cited in: Neuron. 2026 Mar 26:S0896-6273(26)00120-0. [Abstract]
Representative traces and quantification of oEPSC amplitude with OXTR agonist (TGOT, red) or antagonist (Atosiban, blue). The results showed that during high-frequency stimulation (50 Hz), TGOT increased the amplitude of the first oEPSC, while Atosiban (1 μM) reduced it, indicating that OXTR activation strengthened synaptic transmission.
-
Curr Biol
Reduced oxytocin signaling in the dBNST drives the transition from acute pain to persistent anxiety. [Abstract]2025 Sep 26:S0960-9822(25)01182-0. PMID: 41015042
Atosiban acetate purchased from MedChemExpress. Usage Cited in: Curr Biol. 2025 Sep 26:S0960-9822(25)01182-0. [Abstract]
Atosiban (50 μM, 500 nL; bilaterally microinjected into the dorsal bed nucleus of the stria terminalis (dBNST)) administration induced anxiety-like behaviors, as evidenced by reduced exploratory activity in both the OF and EPM tests in sham-treated mice.
-
Transl Psychiatry
Oxytocin attenuates hypothalamic injury-induced cognitive dysfunction by inhibiting hippocampal ERK signaling and Aβ deposition. [Abstract]2024 May 25;14(1):208. PMID: 38796566 -
Neurosci Bull
Sex Differences in Pain Contagion Determined by the Balance of Oxytocin and Corticosterone in the Anterior Cingulate Cortex in Rodents. [Abstract]2025 Aug 6. PMID: 40767942
Atosiban acetate purchased from MedChemExpress. Usage Cited in: Neurosci Bull. 2025 Aug 6. [Abstract]
The icv injection of an oxytocin antagonist Atosiban (OTA, 5 mg/mL; i.c.v.) prevented mechanical allodynia in female cage-mate, female stranger, and male stranger rats; and the icv injection of oxytocin in male stranger rats induced mechanical allodynia after 30-min social interaction with painful CCI rats.
Atosiban acetate purchased from MedChemExpress. Usage Cited in: Neurosci Bull. 2025 Aug 6. [Abstract]
Immunofluorescence showing c-Fos-positive cells in the mPFC (as a control group) and ACC (aACC, mACC, and pACC) after icv injection of an oxytocin antagonist (Atosiban (OTA, 5 mg/mL; i.c.v.) ) in females or oxytocin in males after social interaction with painful CCI rats. Left: representative immunofluorescent staining images. Right: data summary. Tissues were collected immediately after 30-min social interaction (n = 6 rats).
-
Front Neurosci
Enhancement of Oxytocin in the Medial Prefrontal Cortex Reverses Behavioral Deficits Induced by Repeated Ketamine Administration in Mice. [Abstract]2021 Sep 10:15:723064. PMID: 34566567
Atosiban acetate purchased from MedChemExpress. Usage Cited in: Front Neurosci. 2021 Sep 10:15:723064. [Abstract]
The time spent in the social interaction zone was measured in the social interaction test. Pretreatment with atosiban (2.5 ng/μL; once daily for 5 days; injected into the medial prefrontal cortex (mPFC)) 30 min before each oxytocin infusion in the mPFC showed a trend of attenuation of the social interaction behavior, which was improved by oxytocin in ketamine-treated mice, although there was no significant difference between groups.
-
J Pharm Biomed Anal
Analyzing proteolytic stability and metabolic hotspots of therapeutic peptides in two rodent pulmonary fluids. [Abstract]2023 Feb 5:224:115156. PMID: 36463768 -
J Pharm Biomed Anal
Automated high-throughput in vitro assays to identify metabolic hotspots and protease stability of structurally diverse, pharmacologically active peptides for inhalation. [Abstract]2022 Mar 20:211:114518. PMID: 35124452
용액&용해도
DMSO : 100 mg/mL (94.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (47.43 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.37 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.37 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (94.86 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
순도&문서
-
Data Sheet (280 KB)
-
SDS (481 KB)
- English - EN (481 KB)
- Français - FR (481 KB)
- Deutsch - DE (481 KB)
- Norwegian - NO (481 KB)
- Español - ES (481 KB)
- Swedish - SV (481 KB)
- Italian - IT (481 KB)
- Korean - KR (481 KB)
- Portuguese - PT (481 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sanu O, et al. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther Clin Risk Manag. 2010 Apr 26;6:191-9. [Content Brief]
[2]. Philip J Ryan, et al. Oxytocin-receptor-expressing Neurons in the Parabrachial Nucleus Regulate Fluid Intake. Nat Neurosci. 2017 Dec;20(12):1722-1733. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.9486 mL | 4.7428 mL | 9.4855 mL | 23.7138 mL |
| 5 mM | 0.1897 mL | 0.9486 mL | 1.8971 mL | 4.7428 mL | |
| 10 mM | 0.0949 mL | 0.4743 mL | 0.9486 mL | 2.3714 mL | |
| 15 mM | 0.0632 mL | 0.3162 mL | 0.6324 mL | 1.5809 mL | |
| 20 mM | 0.0474 mL | 0.2371 mL | 0.4743 mL | 1.1857 mL | |
| 25 mM | 0.0379 mL | 0.1897 mL | 0.3794 mL | 0.9486 mL | |
| 30 mM | 0.0316 mL | 0.1581 mL | 0.3162 mL | 0.7905 mL | |
| 40 mM | 0.0237 mL | 0.1186 mL | 0.2371 mL | 0.5928 mL | |
| DMSO | 50 mM | 0.0190 mL | 0.0949 mL | 0.1897 mL | 0.4743 mL |
| 60 mM | 0.0158 mL | 0.0790 mL | 0.1581 mL | 0.3952 mL | |
| 80 mM | 0.0119 mL | 0.0593 mL | 0.1186 mL | 0.2964 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Atosiban acetate Related Classifications
HY-17572A Related Classifications
Powered by Bioz